memo - Magazine of European Medical Oncology

, Volume 1, Issue 4, pp 271–275

Latest progress in treatment of gynaecological cancers

ASCO Update
  • 26 Downloads

Summary

The present report gives the scope of relevant contributions focusing on the treatment of gynaecologic malignancies presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held from May 30 to June 3, 2008 in Chicago, Illinois. Some new data will directly influence the routine in gynaecologic oncology, while other data have to await their confirmation in ongoing studies until their clinical impact can be definitively evaluated. Regarding the radiotherapeutic adjuvant management of intermediate-high-risk endometrial cancers, the PORTEC-2 trial clearly demonstrated the non-inferiority of vaginal brachytherapy (VBT) as compared with external beam radiotherapy (EBRT) of the whole pelvis with regard to disease-free and overall survival and revealed a higher rate of treatment-related complications and side-effects for EBRT and consequently a higher quality of life in patients treated with VBT. In chemotherapeutic management of advanced and recurrent cervical cancer the four-armed GOG 204 trial demonstrated the best therapeutic index for the cisplatin-paclitaxel regimen. Hence, the authors advocated that this doublet should be used as a control arm in further GOG protocols investigating this setting. Fundamental changes in the routine first-line chemotherapy for ovarian cancer should be expected from the outcome of the phase III Japanese Gynecologic Oncology Group trial that revealed a survival benefit for weekly dose-dense administration of paclitaxel as compared with standard three-weekly carboplatin-paclitaxel.

Keywords

ASCO Endometrial cancer Cervical cancer Ovarian cancer Chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. J Clin Oncol, 26: 2008 (abstr. LBA5503)Google Scholar
  2. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 355: 1404–1411, 2000PubMedCrossRefGoogle Scholar
  3. Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol, 97: 887–892, 2005PubMedCrossRefGoogle Scholar
  4. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol, 89: 201–209, 2003PubMedCrossRefGoogle Scholar
  5. Sartori E, Laface B, Gadducci A, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer, 13: 458–465, 2003PubMedCrossRefGoogle Scholar
  6. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol, 24: 36–44, 2006PubMedCrossRefGoogle Scholar
  7. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet, 362: 869–875, 2003PubMedCrossRefGoogle Scholar
  8. Ferreira CG, Erlich F, Carmo CC, et al. Erlotinib (E) combined with cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer: a phase II trial. J Clin Oncol, 26: 2008 (abstr. 5511)Google Scholar
  9. Monk BJ, Sill M, McMeekin DS, et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. J Clin Oncol, 26: 2008 (abstr. LBA5504)Google Scholar
  10. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 22: 3113–3119, 2004PubMedCrossRefGoogle Scholar
  11. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol, 23: 4626–4633, 2005PubMedCrossRefGoogle Scholar
  12. Wenzel LB, Huang H, Cella D, et al. Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: a gynecologic oncology group (GOG) study. J Clin Oncol, 26: 2008 (abstr. 5529)Google Scholar
  13. Kurtz E, Besson D, Deslandres M, et al. Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): a phase II GINECO trial. J Clin Oncol, 26: 2008 (abstr. 5512)Google Scholar
  14. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 354: 34–43, 2006PubMedCrossRefGoogle Scholar
  15. Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol, 103: 1–6, 2006PubMedCrossRefGoogle Scholar
  16. Marth C, Walker JL, Barakat RR, et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer, 109: 645–649, 2007PubMedCrossRefGoogle Scholar
  17. Isonishi S, Yasuda M, Takahashi F, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology Group. J Clin Oncol, 26: 2008 (abstr. 5506)Google Scholar
  18. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol, 16: 2620–2624, 1998PubMedGoogle Scholar
  19. Havrilesky LJ, Alvarez AA, Sayer RA, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol, 88: 51–57, 2003PubMedCrossRefGoogle Scholar
  20. Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol, 26: 2008 (abstr. LBA5505)Google Scholar
  21. Bookman MA. GOG 182-ICON5: a five arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin or topotecan in patients with advanced-stage epithelial ovarian and primary peritoneal carcinoma. J Clin Oncol, 25: 2007 (abstr. 5521).Google Scholar
  22. Kristensen G, Kaern J, Baekelandt M, et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol, 26: 2008 (abstr. 5508)Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyInnsbruck Medical UniversityInnsbruckAustria

Personalised recommendations